Lucid Diagnostics (LUCD) EBIAT (2021 - 2025)
Lucid Diagnostics' EBIAT history spans 5 years, with the latest figure at -$16.3 million for Q4 2025.
- For Q4 2025, EBIAT fell 40.94% year-over-year to -$16.3 million; the TTM value through Dec 2025 reached -$58.0 million, down 27.41%, while the annual FY2025 figure was -$58.0 million, 27.41% down from the prior year.
- EBIAT reached -$16.3 million in Q4 2025 per LUCD's latest filing, down from -$10.4 million in the prior quarter.
- In the past five years, EBIAT ranged from a high of -$3.7 million in Q1 2021 to a low of -$26.9 million in Q1 2025.
- Average EBIAT over 5 years is -$12.0 million, with a median of -$11.5 million recorded in 2023.
- Peak YoY movement for EBIAT: crashed 235.89% in 2022, then surged 59.66% in 2025.
- A 5-year view of EBIAT shows it stood at -$11.3 million in 2021, then tumbled by 32.04% to -$14.9 million in 2022, then increased by 27.45% to -$10.8 million in 2023, then dropped by 6.57% to -$11.5 million in 2024, then plummeted by 40.94% to -$16.3 million in 2025.
- Per Business Quant, the three most recent readings for LUCD's EBIAT are -$16.3 million (Q4 2025), -$10.4 million (Q3 2025), and -$4.4 million (Q2 2025).